Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Wellnex Life Ltd ( (AU:WNX) ) just unveiled an update.
Wellnex Life has extended its licensing and supply agreement with Haleon UK Trading Services for the provision of soft gel liquid paracetamol products until 16 March 2027. The deal, maintained through its BSPS Aust subsidiary, strengthens Wellnex Life’s role as a supplier to Haleon’s global brands and underscores the company’s ongoing positioning as a partner of choice in the analgesic and consumer healthcare segment.
The extension secures a multi-year revenue stream from Haleon and reinforces Wellnex Life’s international footprint in over-the-counter pain relief products. By continuing this global partnership, the company enhances its operational visibility and supports its strategy of scaling its proprietary soft gel technology in collaboration with a major consumer healthcare group.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.07 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
More about Wellnex Life Ltd
Wellnex Life Limited is an Australian-listed health and wellness company focused on developing and supplying over-the-counter consumer healthcare products. Through its wholly owned subsidiary BSPS Aust Pty Ltd, the company provides innovative analgesic liquid soft gel formulations to global partners, targeting branded pharmaceutical and consumer health markets.
Average Trading Volume: 79,128
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$5.18M
See more insights into WNX stock on TipRanks’ Stock Analysis page.